Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.

Conclusions: TM inhibits BRAFV600E -driven PTC through inhibition of MEK1/2, supporting clinical evaluation of chronic TM therapy for this disease. Clin Cancer Res; 1-11. ©2018 AACR.
PMID: 30065097 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 31, 2018 Category: Cancer & Oncology Authors: Xu M, Casio M, Range DE, Sosa JA, Counter CM Tags: Clin Cancer Res Source Type: research